Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Anna Binder

Psychiatry Weston, FL Medical Doctor

NPI 1003952029 CMS profile 961476

1495 N Park Dr, Weston, FL 33326

Open in the dashboard

General payments

$810

36 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Anna Binder of Weston, FL is reported in the CMS Open Payments database as having received $810 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $150 2
2022 General $74 4
2021 General $508 26
2020 General $78 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Binder
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Anna Binder were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Anna Binder Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $78 $119 $36–$372 $114
2021 $508 $143 $43–$576 $132
2022 $74 $153 $50–$590 $149
2023 $150 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. AbbVie, Inc. $365 20 payments
  2. Supernus Pharmaceuticals, Inc. $179 3 payments
  3. Lundbeck LLC $59 3 payments
  4. Sunovion Pharmaceuticals Inc. $54 3 payments
  5. Allergan Inc. $41 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $26 1 payment
  7. Almatica Pharma LLC $24 1 payment
  8. Otsuka America Pharmaceutical, Inc. $22 1 payment
  9. ITI, Inc. $20 1 payment
  10. Corium, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $810 36 payments
Products named General payments · program years 2020–2023
  1. VRAYLAR Neuroscience $365 20 payments
  2. QELBREE $179 3 payments
  3. REXULTI $59 3 payments
  4. LATUDA $54 3 payments
  5. VRAYLAR Neuroscience $41 2 payments
  6. TRINTELLIX $26 1 payment
  7. LOREEV XR $24 1 payment
  8. SERTRALINE HCL $24 1 payment
  9. ABILIFY MAINTENA $22 1 payment
  10. CAPLYTA $20 1 payment
  11. Other $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

509

Median for Psychiatry: 574

Drug cost

$11,362

Median for Psychiatry: $27,624

Branded share of claims

17.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 21 $5,113
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 34 $1,190
Ziprasidone Hcl Generic 18 $1,049
Aripiprazole Generic 34 $706
Doxepin Hcl Generic 20 $675
Bupropion Xl Bupropion Hcl Brand 41 $571
Clonazepam Generic 31 $351
Gabapentin Generic 31 $314
Trazodone Hcl Generic 45 $305
Risperidone Generic 35 $301

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$50,833

Medicare's payments for the services billed

Medicare patients

89

Average age 65

Services billed

786

61 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Depression 64%
Diabetes 39%
Arthritis 39%
Ischemic heart disease 27%
Chronic kidney disease 20%
COPD 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record